260 related articles for article (PubMed ID: 38172861)
1. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
4. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
Oriecuia C; Tomasoni D; Sala I; Bonfioli GB; Adamo M; Gussago C; Lombardi CM; Pagnesi M; Savarese G; Metra M; Specchia C
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):147-157. PubMed ID: 37985675
[TBL] [Abstract][Full Text] [Related]
5. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
[TBL] [Abstract][Full Text] [Related]
6. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
7. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials.
Guo Z; Wang L; Yu J; Wang Y; Yang Z; Zhou C
Int J Clin Pharm; 2023 Jun; 45(3):547-555. PubMed ID: 36800144
[TBL] [Abstract][Full Text] [Related]
8. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
11. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
14. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
18. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
Gupta K; Spertus JA; Birmingham M; Gosch KL; Husain M; Kitzman DW; Pitt B; Shah SJ; Januzzi JL; Lingvay I; Butler J; Kosiborod M; Lanfear DE
Circulation; 2023 Jul; 148(3):220-228. PubMed ID: 37191040
[TBL] [Abstract][Full Text] [Related]
19. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
20. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
